Canadian Cancer Society logo

Prostate cancer

You are here: 

Bisphosphonate therapy for prostate cancer

Bisphosphonate therapy is a systemic therapy that may be used in the treatment of prostate cancer to strengthen bone.

Bisphosphonate therapy may be used:

  • to relieve bone pain or to prevent fractures in advanced hormone-refractory prostate cancer (palliative therapy)
  • to prevent osteoporosis in men receiving hormonal therapy

Bisphosphonates are used in combination with other standard treatments for hormone-refractory prostate cancer.

The bisphosphonate used to treat hormone-refractory prostate cancer is:

  • zoledronic acid (Zometa)
    • Zoledronic acid is used to treat men who have little or no pain from bone metastases.
    • This drug is effective in reducing the number of skeletal related events, including bone fractures and the need for radiation to bone metastases.
    • This drug also reduces pain related to bone metastases.
    • The drug has a number of side effects, and men should be informed of the risks and benefits of taking zoledronic acid.

Stories

Researcher Dr John Bell Dr John Bell revealed how cancer-killing viruses attack tumour blood vessels.

Learn more

A home away from home

Illustration of house

For cancer patients who must travel a great distance to get to treatment, Canadian Cancer Society lodges offer a welcoming place to stay.

Learn more